Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Active:	No
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer	NCT ID:	NCT05092360
Trial Phases:	Phase III	Protocol IDs:	ALKS 4230-007 (primary) NCI-2022-04958 ENGOT-OV68 GOG-3063 KEYNOTE-C71
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Mural Oncology, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT05092360

Summary

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in
combination with pembrolizumab versus protocol-specific Investigator's choice
chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or
primary peritoneal cancer.

Objectives

Patients will be centrally allocated in a randomized fashion (3:1:1:3) to receive either:

Arm 1: Nemvaleukin and pembrolizumab combination therapy Arm 2: Pembrolizumab monotherapy
(enrollment completed) Arm 3: Nemvaleukin monotherapy (enrollment completed) Arm 4:
Investigator's choice chemotherapy include one of the following: pegylated liposomal
doxorubicin (PLD), paclitaxel, topotecan, or gemcitabine.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.